Loading stock…

Tango Therapeutics, Inc. (TNGX) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated today

Tango Therapeutics, Inc.

TNGXMarket cap $3.81BPrice $22.6

Country🇺🇸United States

SectorHealthcare

IndustryBiotechnology

Develops cancer drugs by targeting genetic vulnerabilities inside tumor cells, using CRISPR screening to find weaknesses healthy cells don't have. Backed by Gilead and Revolution Medicines, it's betting precision genetics beats traditional chemo.

In Bastion Portfolios?

52W Return+150%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+36%10

Revenue Forecast

Rev CAGR (1y)+20%8

Rev CAGR (3y)-60%1

Rev CAGR (5y)+64%10

Earnings Forecast

EPS Growth Y+1Loss1

EPS Growth Y+2Loss1

EPS Growth Y+3Loss1

Quality

Margins

EBIT Margin-253%1

Net Income Margin-230%1

Free Cash Flow Margin-268%1

Debt

Net Debt/EBITDAna–

Efficiency

ROE-21%1

ROA-19%1

Earnings Stabilityna–

GEAR+VERY WEAK3

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)na–

P/E Ratio (Forward 3y)na–

P/BV3.74

EV Multiples

EV/EBITDA Fwdna–

EV/EBIT Fwdna–

Yield

Free Cash Flow Yield-3.8%2

Dividend Yieldna–

Momentum

Short term

1 month return-6%4

3 month return-26%1

YTD return+155%10

Mid term

Price vs 52wHigh66%3

1 year return+208%10

Long term

3 year return+129%8

5 year return+60%6

Risk Shield

Price Risk

Beta1.23

Volatility94%1

Free Cash Flow

Free Cash Flow Margin-268%1

Free Cash Flow Yield-3.8%2

Quality

ROCE-22%1

Earnings Stabilityna–

Net Debt/EBITDAna–

02Growth

Is it actually growing, and how fast?

TNGXTango Therapeutics

Revenue FY25$62M

GROWTH RATING↗

AVERAGE46 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+36%10

Revenue, next 1Y+20%8

Revenue, next 3Y, CAGR-60%1

Revenue, next 5Y, CAGR+64%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 36%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

The runway holds up: revenue is set to grow 64%/yr over five years.10/10

WATCH

A mid-pack grower, ahead of 46% of companies worldwide.

Revenue is set to shrink 60%/yr over the next 3 years, a little ahead of the market.6/10

WEAKNESSES

Revenue grew 36%/yr over the last 3 years, but it is set to shrink 60%/yr from here.

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A middle-of-the-pack grower heading into decline. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE38 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-6%4

3-month return-26%1

YTD return+155%10

MID & LONG-TERM▾SCORE

% of 52-week high66%3

1-year return+208%10

3-year return+129%8

5-year return+60%6

MOMENTUM ASSESSMENT

STRENGTHS

Strong long-term results. Long-term holders have seen +129% over three years and +60% over five, ahead of 60% of the market.

It's up 208% over the past year, but 34% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming so far this year (+155%).

WATCH

Returns sit at the market level over the past month (-6%).

WEAKNESSES

The stock is underperforming over three months (-26%).

BOTTOM LINE

Steady Compounder

Dependable multi-year returns with a calmer near-term tape. A reliable long-term trend rather than a short-term breakout. The one thing to watch: the stock is underperforming over three months.

04Value

Are you paying a fair price for it?

Stop guessing on Tango Therapeutics, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

TNGXTango Therapeutics

Revenue FY25$62M

GROWTH RATING↗

AVERAGE46 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+36%10

Revenue, next 1Y+20%8

Revenue, next 3Y, CAGR-60%1

Revenue, next 5Y, CAGR+64%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 36%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

The runway holds up: revenue is set to grow 64%/yr over five years.10/10

WATCH

A mid-pack grower, ahead of 46% of companies worldwide.

Revenue is set to shrink 60%/yr over the next 3 years, a little ahead of the market.6/10

WEAKNESSES

Revenue grew 36%/yr over the last 3 years, but it is set to shrink 60%/yr from here.

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A middle-of-the-pack grower heading into decline. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE38 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-6%4

3-month return-26%1

YTD return+155%10

MID & LONG-TERM▾SCORE

% of 52-week high66%3

1-year return+208%10

3-year return+129%8

5-year return+60%6

MOMENTUM ASSESSMENT

STRENGTHS

Strong long-term results. Long-term holders have seen +129% over three years and +60% over five, ahead of 60% of the market.

It's up 208% over the past year, but 34% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming so far this year (+155%).

WATCH

Returns sit at the market level over the past month (-6%).

WEAKNESSES

The stock is underperforming over three months (-26%).

BOTTOM LINE

Steady Compounder

Dependable multi-year returns with a calmer near-term tape. A reliable long-term trend rather than a short-term breakout. The one thing to watch: the stock is underperforming over three months.

04Value

Are you paying a fair price for it?

Stop guessing on Tango Therapeutics, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community